Adapting preclinical benchmarks for first-in-human trials of human embryonic stem cell-based therapies

Stem Cells Translational Medicine

Volumn 5, Issue 8, 2016, Pages 1058-1066

  Barazzetti, Gaia ^a   Hurst, Samia A ^b   Mauron, Alexandre ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

First in human trials; Human embryonic stem cells; Preclinical benchmarks; Research ethics; Translational research

Indexed keywords

CELL THERAPY; HUMAN; HUMAN EMBRYONIC STEM CELL; HUMAN EXPERIMENT; IDENTITY; LEARNING; PRECLINICAL STUDY; PREDICTION; PUBLICATION; RESEARCH ETHICS; SAFETY; SCIENTIST; TRANSLATIONAL RESEARCH; UNCERTAINTY; ADVERSE EFFECTS; ANIMAL MODEL; BENCHMARKING; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); EMBRYONIC STEM CELL; ETHICS; LEGISLATION AND JURISPRUDENCE; MANAGEMENT; METHODOLOGY; PARKINSON DISEASE; PATIENT SAFETY; PHENOTYPE; PROCEDURES; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

BENCHMARKING; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; EMBRYONIC STEM CELLS; HUMANS; MODELS, ANIMAL; PARKINSON DISEASE; PATIENT SAFETY; PHENOTYPE; POLICY MAKING; RESEARCH DESIGN; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84978646009     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0222     Document Type: Article

References (51)

1. Doi D, Morizane A, Kikuchi T et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson’s disease. STEM CELLS 2012;30:935–945.
2. Ratcliffe E, Glen KE, Naing MW et al. Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: Case studies. Br Med Bull 2013;108: 73–94.
3. Redmond DE Jr.,McEntire CRS, Kingsbery JP et al. Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson’s model. Mol Ther 2013;21: 2160–2168.
4. Sundberg M, Bogetofte H, Lawson T et al. Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. STEM CELLS 2013;31:1548–1562.
5. Asterias Biotherapeutics (initiated in 2010 by Geron Corp.). Safety study of GRNOPC1 in spinal cord injury. Available at http://clinicaltrials.gov/ ct2/show/NCT01217008?term=geron&rank=9. Accessed July 1, 2015.
6. Ocata Therapeutics (initiated in 2011 by Advanced Cell Technology). Sub-retinal transplantation of hESC derived RPE (MA09-hRPE) cells in patients with Stargardt’s macular dystrophy. Available at http://clinicaltrials.gov/ct2/show/study/ NCT01345006?term=NCT01345006&rank=1. Accessed July 1, 2015
7. Ocata Therapeutics (initiated in 2011 by Advanced Cell Technology). Safety and tolera-bility of sub-retinal transplantation of hESC derived RPE (MA09-hRPE) cells in patients with advanced age related macular degeneration (Dry AMD). Available at http://clinicaltrials.gov/ct2/ show/NCT01344993?term=rpe+advanced+cell+ technology&rank=1. Accessed July 1, 2015.
8. Dawson L, Bateman-House AS, Mueller Agnew D et al. Safety issues in cell-based intervention trials. Fertil Steril 2003;80:1077–1085.
9. Kimmelman J, Baylis F, Glass KC. Stem cell trials: Lessons from gene transfer research. Hastings Cent Rep 2006;36:23–26.
10. Master Z, McLeod M, Mendez I. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson’s disease. J Med Ethics 2007;33:169–173.
11. Mathews DJH, Sugarman J, Bok H et al. Cell-based interventions for neurologic conditions: Ethical challenges for early human trials. Neurology 2008;71:288–293.
12. Hess PG. Risk of tumorigenesis in first-in-human trials of embryonic stem cell neural derivatives: Ethics in the face of long-term uncertainty. Account Res 2009;16:175–198.
13. Bretzner F, Gilbert F, Baylis F et al. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 2011;8:468–475.
14. Solbakk JH, Zoloth L. The tragedy oftrans-lation: The case of “first use” in human embryonic stem cell research. Cell Stem Cell 2011;8: 479–481.
15. Dunnett SB, Rosser AE. Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease. Neurobiol Dis 2014;61: 79–89.
16. Hey SP, Kimmelman J. The risk-escalation model: A principled design strategy for early-phase trials. Kennedy Inst Ethics J 2014;24: 121–139.
17. Hurst SA, Mauron A, Momjian S et al. Ethical criteria for human trials of stem-cell-derived dopaminergic neurons in Parkinson’s disease. AJOB Neurosci 2015;6:52–60.
18. Kimmelman J. Gene Transfer and the Ethics of First-in-Human Research.Lostin Translation. New York: Cambridge University Press, 2010.
19. Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet 2014;15: 82–92.
20. International Conference on Harmonisa-tion of Technical Requirements for Registration of Pharmaceuticals for Human Use. Impurities in new drug substances, Q3A(R2) (1994). 2006. Available at http://www.ich.org/home.html. Accessed July 1, 2015.
21. International Conference on Harmonisa-tion of Technical Requirements for Registration of Pharmaceuticals for Human Use. Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances, Q6A (1997). 1999. Available at http://www.ich.org/home.html. Accessed July 1, 2015.
22. International Conference on Harmonisa-tion of Technical Requirements for Registration of Pharmaceuticals for Human Use. Stability testing of new drug substances and products, Q1A(R2) (1992). 2003. Available at http://www.ich.org/home.html. Accessed July 1, 2015.
23. International Conference on Harmonisa-tion of Technical Requirements for Registration of Pharmaceuticals for Human Use. Preclinical safety evaluation of biotechnology-derived pharmaceuticals, S6 (1996). 1997. Available at http://www.ich.org/home.html. Accessed July 1, 2015.
24. International Conference on Harmonisa-tion of Technical Requirements for Registration of Pharmaceuticals for Human Use. Note for guidance specifications: Test procedures and acceptance criteria for biotechnological/biological products, Q6B (1998). 1999. Available at http://www.ich.org/home.html. Accessed July 1, 2015.
25. International Conference on Harmonisa-tion of Technical Requirements for Registration of Pharmaceuticals for Human Use. Quality of biotechnological products: Stability testing of biotechnological/biological products, Q5C. 1995. Available at http://www.ich.org/home.html. Accessed July 1, 2015.
26. Food and Drug Administration. Biological products: General (CFR, Title 21, Part 600). Available at https://http://www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch. cfm?CFRPart=600. Accessed July1, 2015.
27. Food and Drug Administration. General biological products standards (CFR, Title 21, Part 610). Available at http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? CFRPart=610. Accessed July 1, 2015.
28. European Medicines Agency. Guideline on human cell-based medicinal products. 2008. Available at http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/ 2009/09/WC500003894.pdf. Accessed July 1, 2015.
29. Food and Drug Administration. Human cells, tissues, and cellular and tissue-based prod-ucts(CFR, Title 21,Part 1271).Availableathttp:// www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm?CFRPart=1271&showFR=1. Accessed July 1, 2015.
30. Food and Drug Administration. Center for Biologics Evaluation and Research (CBER), Guidance for reviewers. Instruction and template for chemistry, manufacturing, and control (CMC) reviewers of human somatic cell therapy investigational new drug applications (INDs). 2003. Available at http://www.fda.gov/OHRMS/ DOCKETS/98fr/03d0349gdl.pdf. Accessed July 1, 2015.
31. Food and Drug Administration. Proposed approach to regulation of cellular and tissue-based products. 1997. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ Guidances/Tissue/UCM062601.pdf.Accessed July1, 2015.
32. European Medicines Agency. Reflection paper on stem cell-based medicinal products, 2011. Available at http://www.cirm.ca.gov/ files/PDFs/RMC/EMA_Final_Reflection_Paper. pdf. Accessed July 1, 2015.
33. International Society for Stem Cell Research. Guidelines for the clinical translation of stem cells. 2008. Available at http://www.isscr. org/home/publications/ClinTransGuide. Accessed July 1, 2015.
34. National Institutes of Health. 10. Assessing human stem cell safety. In: Stem Cell Information. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services. 2009. Available at http://stemcells. nih.gov/info/scireport/pages/chapter10.aspx.Accessed July 1, 2015.
35. Food and Drug Administration. CTGTAC Meeting # 45, Cellular therapies derived from human embryonic stem cells – Considerations for pre-clinical safety testing and patient monitoring (April 10, 2008). Available at http:// www.fda.gov/ohrms/dockets/ac/08/briefing/ 2008-0471B1_1.pdf. Accessed July 1, 2015.
36. InternationalConferenceonHarmonisation ofTechnicalRequirementsforRegistrationofPhar-maceuticals for Human Use. Good manufacturing practice guide for active pharmaceutical ingredients, Q7. 2000. Available at http://www.ich.org/ home.html. Accessed July 1, 2015.
37. Food and Drug Administration. Guidance for industry. CGMP for Phase 1 investigational drugs, Center for Drug Evaluation and Research (CDER), CenterforBiologicsEvaluationandResearch(CBER), Office of Regulatory Affairs (ORA), July 2008. Available at http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/ guidances/ucm070273.pdf. Accessed July 1, 2015.
38. Catalano J. The International Conference on Harmonization (ICH) and its relevance to cell therapy. ISCT 6th Annual Somatic Cell Therapy Symposium 2006. Available at http://www.bcg-usa.com/regulatory/docs/FDA_Presentations_ Publications/SP9D06.pdf. Accessed July 1, 2015.
39. Deal G. Stem cell therapy regulations. The US vs the EU. Regulatory Rapporteur 2009;6:4–6.
40. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355:1730–1735.
41. Fink DW Jr. FDA regulation of stem cell-based products. Science 2009;324:1662–1663.
42. Regulation (EC) No. 1394/2007 of the European Parliament and of the Council on Advanced Therapy Medicinal Products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union L 324/121.
43. Preynat-Seauve O, Burkhard PR, Villard J et al. Pluripotent stem cells as new drugs? The example of Parkinson’s disease. Int J Pharm 2009;381:113–121.
44. Bongso A, Fong C-Y, GauthamanK. Taking stem cells to the clinic: Major challenges. J Cell Biochem 2008;105:1352–1360.
45. Salmikangas P, Flory E, Reinhardt J et al. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010; 53:24–29.
46. Kriks S, Shim J-W, Piao J et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 2011;480:547–551.
47. Unger C, Skottman H, Blomberg P et al. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet 2008;17(R1):R48–R53.
48. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders–time for clinical translation? J Clin Invest 2010;120:29–40.
49. Steinbeck JA, Studer L. Moving stem cells to the clinic: Potential and limitations for brain repair. Neuron 2015;86:187–206.
50. Barker RA. Developing stem cell therapies for Parkinson’s disease: Waiting until thetimeisright.CellStemCell 2014;15: 539–542.
51. Potts LF, Wu H, Singh A et al. Modeling Parkinson’s disease in monkeys for translational studies, a critical analysis. Exp Neurol 2014;256: 133–143.